|
SYNLAB AG / Key word(s): Agreement/Strategic Company Decision SYNLAB AG: Cinven announces public acquisition offer | Conclusion of Investment Agreement 29-Sep-2023 / 08:17 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News – a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. SYNLAB AG (“SYNLAB”; FSE: SYAB) has today signed an investment agreement (“Investment Agreement”) with Ephios Luxembourg S.à r.l. and its subsidiary Ephios Bidco GmbH, two holding companies controlled by investment funds advised by Cinven Limited.
Concurrently, Ephios Luxembourg S.à r.l. announced its decision to make a voluntary public acquisition offer to the shareholders of SYNLAB to acquire all shares outstanding of SYNLAB (“Offer”) not directly held by it at a price of €10.00 per SYNLAB share. Ephios Luxembourg S.à r.l. already holds approx. 43.24% of the voting rights in SYNLAB. The Offer will not be subject to a minimum acceptance threshold. As a basis for the Offer, the Investment Agreement was concluded to specify the offer process and provide for the future cooperation. This includes, among other things, agreements regarding the support of the corporate and growth strategies of the Company as well as the interests of employees of SYNLAB Group. End of Inside Information 29-Sep-2023 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
Beckman Coulter receives FDA warning letter
Listen to the article 3 min This audio is auto-generated. Please let us know if you have feedback. Dive Brief: Beckman Coulter received a warning
April 5, 2024